Era Biotech, S.a.

Zera Intein Protein Solutions, S.l.

Pablo Marzábal Luna

Margarita Torrent Quetglas

Blanca Llompart Royo

Miriam Bastida Virgili

Edward Peter Rybicki

Peter Bernard Heifetz

Ann Elizabeth Meyers

Inga Isabel Hitzeroth

Roser Pallisse Bergwerf

Maria Dolores Ludevid Múgica

Peter Öhlschläger

Ma Immaculada Ilop Tous

Kevin James O'Connor

Ma Dolores Ludevid Múgica

François Devesa

Minu Joseph

Maria Immaculada Llop Tous

Peter ÖHLSCHLÄGER

Edwar Peter Rybicki

Joseph Minu

María Dolores Ludevid Mugica

Mª Inmaculada Llop

Kevin James O Connor

Polypeptide sequences for inducing recombinant protein bodies are described. The sequences comprise a polyproline II (PPII) structure and/or a proline-rich sequence between two cysteine residues on either end. Recombinant protein bodies are useful for protein production because they allow for simple and efficient purification of high quantities of recombinant protein. In addition, other methods of using recombinant protein bodies, for example, in vaccination and food products, are also described.

Recombinant protein body-inducing polypeptides

An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.

Recombinant protein bodies as immunogen-specific adjuvants

A fusion protein that is expressed in a recombinant protein body-like assembly (RPBLA) in host eukaryotic cells and organisms is disclosed. More particularly, a biologically active polypeptide fused to a protein sequence that mediates the induction of RPBLA formation is expressed and accumulated in host cells after transformation with an appropriate vector. The eukaryotic host cell does not produce protein bodies in the absence of the fusion protein. Methods for preparing and using the RPBLAs and the fusion protein are also disclosed, as are nucleic acid molecules that encode the fusion proteins.

Production of biologically active proteins

Growing community of inventors

Barcelona, Spain

Pablo Marzábal Luna